77206-89-4

Usage

Uses

Used in Pharmaceutical Industry:
(2-chloro-6-methylphenyl)methanol is used as an intermediate in the synthesis of various bioactive molecules, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
(2-chloro-6-methylphenyl)methanol is used as a starting material for the production of herbicides, insecticides, and other agricultural chemicals, helping to improve crop protection and yield.
It is important to handle and use (2-chloro-6-methylphenyl)methanol with caution, as it may have hazardous properties and should be managed by trained professionals in a controlled laboratory environment.

Upstream product

• 1194-64-5 2-chloro-6-methylbenzaldehyde 
• 21327-86-6 2-chloro-6-methylbenzoic acid 
• 87-63-8 2-chloro-6-methylaniline 

Downstream Products

• 55676-90-9 alpha,2-dichloro-6-methyltoluene 
• 76574-40-8 2-(2-chloro-6-methyl-phenyl)acetonitrile 
• 76574-62-4 6-(2-Chloro-6-methyl-phenyl)-pyrido[2,3-d]pyrimidin-7-ylamine 
• 76574-82-8 6-(2-chloro-6-methylphenyl)-2-methylpyrido[2,3-d]-pyrimidin-7-amine 
• 1200397-45-0 ethyl 2-(3-(2-chloro-6-methylbenzyloxy)phenyl)acetate 
• 1562195-17-8 1-(2-chloro-6-methylbenzyl)-4-fluoro-3-iodo-1H-indazole 
• 1562195-20-3 methyl 4-(1-(2-chloro-6-methylbenzyl)-4-fluoro-1H-indazol-3-yl)-5-fluoro-2-methoxybenzoate 
• 1562193-97-8 4-(1-(2-chloro-6-methylbenzyl)-4-fluoro-1H-indazol-3-yl)-5-fluoro-2-hydroxybenzoic acid 
• 259733-13-6 2-(bromomethyl)-1-chloro-3-methylbenzene 
• 1194-64-5 2-chloro-6-methylbenzaldehyde 
• 1200397-26-7 2-(3-(2-chloro-6-methylbenzyloxy)phenyl)acetic acid 

Relevant academic research and scientific papers

COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION

The present disclosure relates generally to compounds and pharmaceutical compositions for the selective inhibition of histone lysine demethylase5 (KDM5), particularly KDM5B, and methods of their use in treating conditions and diseases associated with KDM5 activity.

CYCLIC COMPOUND

The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of autoimmune disease and/or inflammatory disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

DIFLUOROMETHYLENE COMPOUND

The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.

N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

COMPOUNDS AND METHOD FOR REDUCING URIC ACID

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In Formula (I) m is 0, 1, 2, 3 or 4; n is 0 or 1; m + n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, methyl or ethyl and R12 is hydrogen or methyl, or R6 is hydroxy and R12 is hydrogen, or R6 is O and R12 is absent, or R6 and R12 together are -CH2CH2-. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of Formula (I) by a ring carbon; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl. The uric acid-lowering effects of the Compounds of Formula (I) are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, and cognitive impairment.

NITROGENOUS HETEROCYCLIC DERIVATIVE HAVING 2,6-DISUBSTITUTED STYRYL

The invention provides a novel nitrogen-containing heterocyclic derivative having 2,6-disubstituted styryl and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the nitrogen-containing heterocyclic derivative and a pharmaceutically acceptable salt thereof, in particular, a pharmaceutical composition effective as a sodium channel inhibitor, having an excellent analgesic action especially on neuropathic pain with minimized side effects.

Antihypertensive Activity of 6-Arylpyridopyrimidin-7-amine Derivatives

A series of 51 6-arylpyridopyrimidin-7-amine derivatives was prepared and evaluated for antihypertensive activity in the conscious spontaneously hypertensive rat.A number of these compounds, notably 6-(2,6-dichlorophenyl)-2-methylpyridopyrimidin-7-amine (36), lowered blood pressure in these rats in a gradual and sustained manner to normotensive levels at oral doses of 10-50 mg/kg.Normalized blood pressure levels could then be maintained by single daily oral doses.The effect of structural variation in the 6-aryl group and in the 2 and 4 positions of the pyridopyrimidine ring on activity is reported and discussed.

6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives

6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives and their pharmaceutically acceptable acid addition salts are useful in the treatment of hypertension.